DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)

Information source: Boehringer Ingelheim
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Telmisartan (Drug); Telmisartan hydrochlorothiazide (Drug)

Phase: N/A

Status: Completed

Sponsored by: Boehringer Ingelheim

Summary

The primary objective was to evaluate, through the use of Home blood pressure monitoring (HBPM), the degree of BP control in the early morning hours after 8 weeks of treatment in patients with essential hypertension under treatment with Micardis, Telmisartan or Micardis Plus, Telmisartan hydrochlorothiazide. The co-primary endpoints were the degree of BP control, and change from baseline until study end in mean systolic blood pressure (mSBP) and mean diastolic blood pressure (mDBP) HBPM in the early morning hours after 8 weeks of treatment with Micardis, Telmisartan or Micardis Plus, Telmisartan hydrochlorothiazide. Secondary endpoints were office BP control rates, office BP response rates, and reduction in mSBP and mDBP Office blood pressure measurement (OBPM) from baseline to final visit, discontinuations and tolerability

Clinical Details

Official title: A Study of a Hypertensive Population Under Treatment With Micardis and Micardis Plus Under Real Clinical Conditions With the Goal to Control the Early Morning BP Rise (SURGE II)

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Change of degree of Blood Pressure (BP) control in the early morning hours

Change from baseline in mSBP and mDBP by HBPM in the early morning

Secondary outcome:

Change from baseline in office BP control rates

Change from baseline in office BP response rates

Reduction in mSBP and mDBP by OBPM

Number of patients with adverse events

Global Assessment of tolerability by investigator on a 6-point scale

Global assessment efficacy by investigator on 6-point scale

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Patients male or female between 18 and 80 years of age

- Patients with mild to moderate essential hypertension

- Patients diagnosed with hypertension that are not currently taking antihypertensive

medication or previously diagnosed hypertensive patients who are uncontrolled with their current treatment Exclusion Criteria:

- Pre-menopausal women who have no birth control, who are pregnant or nursing

- Patients with advanced hepatic impairment or advanced renal impairment

- Patients with New York Heart Association (NYHA) functional class III or IV congestive

heart failure (CHF), unstable angina, acute myocardial infarction, heart surgery or stroke within the previous six months

- Patients with any type of relevant arrhythmia according to the assessment of the

investigator

- Patients with any valvular disease with hemodynamic repercussion

- Patients receiving chronic administration of oral anticoagulants or digoxin

- Patients with known hypersensitivity to any component in the formulation of

Micardis®, Telmisartan or Micardis Plus®, Telmisartan hydrochlorothiazide

- Patients with previous history of angioedema associated with angiotensin converting

enzyme (ACE) inhibitors

- Patients with severe, uncontrolled hypertension or any form of secondary hypertension

- Patients with any other clinical conditions which, in the opinion of the

investigator, would not allow for the safe completion of the protocol

Locations and Contacts

Additional Information

Starting date: August 2005
Last updated: September 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017